Calithera Biosciences has set the terms of its upcoming IPO, planning to list 6 million shares at an estimated price between $13 and $15. The company has filed to list on the NASDAQ under the symbol CALA; it would command a market cap of over $222 million if priced at the midpoint of its range. Calithera develops drug platforms that inhibit tumor metabolism and promote the body's cancer-fighting immune cells. Proceeds from the IPO will be used to further clinical trials for several product candidates and fund research for additional candidate programs. Major stockholders include Delphi Ventures (19.5% pre-IPO stake), Morgenthaler (18.3%) Advanced Technology Ventures (18.3%) and Adage Capital Management (18.1%), among others.